CDSCO Issues Nationwide Alert After Theft of Sanofi’s Lantus Insulin Batch: What Patients and Providers Need to Know

Spread the Message

Read Time:4 Minute, 32 Second

NEW DELHI — India’s apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO), has issued an urgent nationwide advisory following the theft of a significant shipment of Lantus SoloStar (Insulin Glargine). The theft, which occurred during transit from Odisha to Kolkata on March 2, 2026, has sparked immediate public health concerns regarding the safety, potency, and storage integrity of the life-saving medication.

The alert specifically identifies Batch No. 5F0347B. Regulatory officials warn that because the stolen units have exited the controlled “cold chain” supply system, they may have been exposed to temperature fluctuations that could render the insulin ineffective or even dangerous for the millions of Indians living with diabetes.

The Incident: A Breach in the Cold Chain

The theft was reported while the consignment was being transported from Jagmohanpur, Keonjhar Road in Odisha, to a Sanofi India Limited distribution agent in Kolkata. While local law enforcement in Odisha continues its investigation, the CDSCO’s Enforcement & Intelligence Cell has moved rapidly to notify state drug controllers, the All India Organisation of Chemists and Druggists (AIOCD), and healthcare facilities across the country.

The primary concern is not just the loss of the physical product, but the compromise of the cold chain. Lantus SoloStar is a biological product that requires strict refrigeration between 2°C and 8°C to maintain its molecular stability. Once these conditions are breached—especially in India’s often harsh ambient temperatures—the insulin begins to degrade.

Identifying the Affected Product:

Brand Name: Lantus SoloStar (Insulin Glargine Injection IP)
Manufacturer: Sanofi India Limited
Batch Number: 5F0347B
Strength: 100 IU/mL (r-DNA origin)
Format: Pre-filled SoloStar pens

Why Temperature Matters: The Science of Insulin Stability

Insulin is a protein-based hormone. When exposed to heat or light, it undergoes hydrolytic reactions, leading to the formation of higher molecular weight complexes.

According to data on insulin stability, a single vial stored at room temperature can lose approximately 1.5% of its potency per month. In a tropical climate where temperatures frequently exceed 30°C, this degradation happens much faster. For a patient, using “spoiled” insulin is not a neutral event; it can lead to:

Unpredictable Blood Glucose: The insulin may not lower blood sugar as expected, leading to Hyperglycemia (high blood sugar).
Increased Complications: Chronic high sugar levels increase the risk of diabetic ketoacidosis (DKA), a life-threatening condition, as well as long-term damage to the heart and kidneys.
Injection Site Reactions: Degraded insulin can cause lipohypertrophy (fatty lumps under the skin), which further impairs future insulin absorption.

Expert Perspectives: A Growing Threat to Public Health

India is often referred to as the “diabetes capital of the world,” with over 101 million adults affected according to the 2023 ICMR-INDIAB study. For many, Lantus—a long-acting basal insulin—is the foundation of their daily survival.

“Insulin is a life-saving biologic; any loss in potency due to temperature excursion can cause severe glycemic instability,” says Dr. V. Mohan, Chairman of the Madras Diabetes Research Foundation. “Patients must remain vigilant, purchasing only from licensed outlets and reporting any unusual blood sugar spikes immediately.”

Dr. Shashank Joshi, President of the Indian Diabetes Society, notes that this incident follows a troubling pattern, including the 2025 theft of Novo Nordisk insulin batches. “These alerts highlight critical gaps in transit security and cold chain logistics. There is absolutely no room for complacency in diabetes care. We need better digital tracking and blockchain-enabled transparency in our supply chains.”

Advisory for Patients and Healthcare Providers

The CDSCO has outlined specific steps to mitigate the risk of this stolen batch reaching the public:

For Patients and Consumers:

Check Your Pen: Inspect the batch number on any Lantus SoloStar pen before use. If it matches 5F0347B, do not use it.
Source Wisely: Only purchase insulin from authorized pharmacies that provide a valid tax invoice. Avoid “grey market” or heavily discounted online sources that cannot verify storage history.
Monitor Symptoms: If you experience unexplained high blood sugar levels or localized skin reactions after an injection, contact your physician immediately.

For Healthcare Professionals:

Verify Stock: Ensure hospital and clinic pharmacies have screened their current inventory for the affected batch.
Patient Education: Proactively inform patients about the theft and teach them how to identify batch numbers.
Report ADRs: Any Adverse Drug Reactions (ADRs) suspected to be linked to this batch should be reported to the National Pharmacovigilance Centre.

The Broader Context: Supply Chain Vulnerabilities

The theft of high-value biologics like Lantus (which retails for approximately ₹800–₹1000 per pen) points to a sophisticated challenge in pharmaceutical logistics. While Sanofi is cooperating with authorities, the incident underscores the difficulty of monitoring goods in a country where a significant portion of the population lacks consistent access to refrigeration.

Critics and industry experts suggest that until GPS-enabled cold chain monitoring and traceable QR codes are mandatory for every unit of insulin, the risk of compromised “black market” drugs will remain a persistent threat to India’s most vulnerable patients.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.